A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).
暂无分享，去创建一个
Sung-Bae Kim | M. Brose | S. Sherman | M. Krzyzanowska | R. Elisei | M. Shah | L. Wirth | Matthew H Taylor | K. Newbold | B. Robinson | M. Tahara | M. Habra | Junming Zhu | N. Kiyota | A. Hoff | A. Gianoukakis | C. Dutcus | B. de las Heras | Matthew H. Taylor | M. Shah